Physician profile
Elie Abed
NPI 1235579202
$9,639.70
in general payments reported to CMS, 2019-2025
40 companies · $2,046 in 2025
The $2,046 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $301 · 2021: $423 · 2022: $1,006 · 2023: $2,557 · 2024: $2,690 · 2025: $2,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,292.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,218.44 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $867.53 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $671.63 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $630.19 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $627.50 | 2019-2023 | Farxiga |
| Dexcom, INC. | $570.38 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novartis Pharmaceuticals Corporation | $445.39 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.12 | 2020-2025 | Jardiance |
| Esperion Therapeutics, INC. | $418.01 | 2021-2025 | Nexletol, Nexlizet |
| Amgen INC. | $387.37 | 2019-2025 | Evenity, Repatha, Repatha |
| Amneal Pharmaceuticals LLC | $326.80 | 2024-2025 | Unithroid |
| Insulet Corporation | $326.01 | 2023-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $315.49 | 2021-2025 | Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $301.09 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $239.59 | 2019-2024 | Korlym |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $239.00 | 2021-2025 | Afrezza |
| Kyowa Kirin, INC. | $183.62 | 2023-2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $167.69 | 2022-2023 | Strensiq |
| Abbvie INC. | $150.23 | 2021-2025 | Synthroid |
| Janssen Pharmaceuticals, INC | $130.65 | 2019-2021 | |
| Antares Pharma, INC. | $126.57 | 2019-2023 | Xyosted, Nocdurna, Tlando |
| Currax Pharmaceuticals LLC | $123.36 | 2022-2025 | Contrave |
| Recordati_rare_diseases_inc. | $99.40 | 2025 | Isturisa |
| Astellas Pharma US INC | $92.31 | 2024-2025 | Veozah |
| Beta Bionics, INC. | $69.76 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascendis Pharma Endocrinology INC | $59.67 | 2023-2025 | Yorvipath |
| Medtronic, INC. | $52.46 | 2022 | |
| Intra-Sana Laboratories | $51.34 | 2024-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Sanofi-Aventis U.S. LLC | $47.66 | 2023-2025 | |
| Amarin Pharma, INC. | $47.31 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $39.92 | 2019-2021 | |
| Rhythm Pharmaceuticals, INC. | $30.81 | 2025 | Imcivree |
| Endo Pharmaceuticals INC. | $28.61 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $27.33 | 2025 | |
| Gilead Sciences, INC. | $25.16 | 2019 | |
| Sequel Med Tech, LLC | $23.01 | 2025 | Twiist |
| Surmodics, INC. | $15.87 | 2023 | Pounce Venous Thrombectomy System, Pounce Thrombectomy, Sublime Radial Access 018 Rx Pta Dilatation Catheter |
| Halozyme INC | $14.04 | 2023 | |
| Merck Sharp & Dohme LLC | $12.73 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elie Abed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.